Myelodysplastic syndromes are a group of bone marrow disorders where blood cells don't develop properly, causing low blood counts and a risk of progression to acute myeloid leukemia. Treatment ranges from supportive care and blood transfusions to hypomethylating agents like azacitidine and decitabine, stem cell transplant, and newer targeted drugs for specific genetic mutations.
What's actually going on in research
Trials are testing venetoclax combinations, oral hypomethylating agents that may work better than infusions, drugs targeting specific mutations like TP53 or splicing factors, and immune checkpoint inhibitors. Researchers are also studying ways to predict who will progress to leukemia and how to reduce transfusion dependence in lower-risk disease.
Venetoclax combinations
This drug blocks a protein that helps cancer cells survive and is already approved for some leukemias. Trials are testing it with azacitidine or decitabine to see if the combination produces better responses than standard treatment.
Splicing modulators
About half of people with MDS have mutations in genes that control how cells read their genetic code. Drugs targeting these splicing errors are showing promise in early studies.
Oral hypomethylating agents
Pills that work like azacitidine and decitabine but can be taken at home instead of requiring infusion center visits. Early data suggest they may produce similar responses with better convenience.
What to know before you search
Eligibility typically depends on MDS risk score, blood count levels, prior treatments, specific genetic mutations, and whether you're a transplant candidate.
What types of trials are currently open
- Treatment trials — Testing new drugs or drug combinations, often comparing them to azacitidine or other standard treatments to see if they improve blood counts or survival.
- Targeted therapy trials — Testing drugs aimed at specific genetic mutations found in your bone marrow biopsy, such as TP53 mutations or splicing factor mutations.
- Stem cell transplant trials — Studies testing ways to make transplant safer or more effective, or to decide who benefits most from transplant versus medical treatment.
- Lower-risk MDS trials — Testing treatments to improve blood counts and reduce transfusion needs in people with less aggressive disease.
- Maintenance trials — Testing whether continuing treatment after initial response can delay progression to leukemia or keep blood counts stable longer.
Recently added Myelodysplastic Syndromes trials
Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS
This study will explore the efficacy and safety of ivosidenib as maintenance therapy in patients with IDH1-mutated AML and high-risk MDS who are ineligible for transplantation, along with accompanying molecular biomarker research. Patients who meet the eligibility criteria will receive ivosidenib treatment until disease progression or unacceptable toxicity. This study will provide an effective maintenance treatment option for transplant-ineligible patients with IDH1-mutated AML and high-risk MDS.
Haplo-Cord HSCT for AML/MDS
This study aims to investigate the clinical efficacy of haploidentical-cord blood hematopoietic stem cell transplantation in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), and to analyze the impact of different engraftment patterns (haploidentical engraftment versus cord blood engraftment) on clinical outcomes. By comparing the efficacy of haploidentical-cord blood transplantation in different subtypes of AML and MDS, this research will explore its unique advantages and comparative effectiveness relative to conventional transplantation strategies, so as to provide new evidence for clinical practice. Specific research objectives I. To evaluate the efficacy of haploidentical-cord blood hematopoietic stem cell transplantation for AML and high-risk MDS, including the speed of hematopoietic recovery, immune tolerance, and long-term survival rates. II. To compare the effects of different engraftment patterns (haploidentical engraftment vs. cord blood engraftment) on quality of life, immune tolerance, early complications, and long-term prognosis. III. To identify the clinical advantages and indications of haploidentical-cord blood transplantation through data analysis, and to provide a theoretical basis for clinical decision-making. Novelty of the Study I. Innovation in Hematopoietic Stem Cell Infusion Schedule The present study employs a sequential infusion strategy: haploidentical stem cells are infused on Day 0, and umbilical cord blood cells are infused on Day +6 after transplantation.In contrast to the conventional approach used at most domestic and international centers (including the uzhou Protocol), in which both stem cell sources are infused simultaneously on Day 0, the current protocol delays cord blood infusion. This design confers potential advantages for immune reconstitution and long-term cord blood engraftment. II. Unique Myeloablative Conditioning Regimen The conditioning regimen used in this study is as follows: Fludarabine 25 mg/m² for 5 days, Cytarabine 2 mg/m² for 5 days, intravenous Busulfan 3.2 mg/kg for 3 days, ATG 5 mg/m² for 2 days, Melphalan 60 mg/m² for 2 days, and CTX 50.0 mg/kg daily for 2 days. (For patients in complete remission (CR) with negative MRD before transplantation, Fludarabine and Cytarabine are administered for 3 days instead of 5 days.) Distinct from regimens at other centers, our team administers cyclophosphamide within the critical window after haploidentical stem cell infusion but before cord blood infusion, establishing a novel sequential conditioning model. This approach balances myeloablative intensity and immunomodulation, creating a favorable environment for subsequent long-term cord blood engraftment. III. Engraftment Outcomes and Clinical Value Preliminary clinical experience demonstrates that haplo-cord sequential transplantation following the FA5Cy2Bu3 conditioning regimen combined with low-dose ATG/PTCY can achieve long-term cord blood engraftment in approximately 50% of patients. By comparison, other domestic protocols (e.g., the Suzhou Protocol) rarely result in sustained cord blood engraftment. Achievement of long-term cord blood engraftment is clinically meaningful for reducing relapse rates, lowering the incidence and severity of graft-versus-host disease (GVHD), and improving patient prognosis. These outcomes represent a key advantage of the present protocol.
Find Myelodysplastic Syndromes trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.